Crucell, Symphogen, UCB deal

CRXL announced the termination of licenses that granted UCB and Symphogen rights to use CRXL's PER.C6 cell lines to produce antibodies (see BioCentury, July 25, 2005, & March 20, 2006). CRXL said the ...